Results 1 to 10 of about 5,655 (94)
Immunological Medicine, 2021 Chimeric antigen receptor (CAR) is generated by fusing a cancer-specific antibody’s antigen recognition site with costimulatory molecules such as CD28 and CD3ζ. T cells transduced with CAR recognizes cancer-specific antigens and kill cancer cells.
Naoki Hosen
doaj +6 more sources
Donor T cells for CAR T cell therapy
Biomarker Research, 2022 Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed.
Tiffany C. Y. Tang +5 more
doaj +4 more sources
CAR T Cell Therapy for Neuroblastoma [PDF]
Frontiers in Immunology, 2018 Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with debilitating long term sequelae from treatment. Even after integration of anti-GD2 monoclonal antibody therapy into standard, upftont protocols, 5-year overall ...
Rebecca M. Richards +2 more
doaj +3 more sources
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
Mediterranean Journal of Hematology and Infectious DiseasesChimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes.
Ugo Testa +4 more
doaj +4 more sources
Reactions WeeklyChimeric antigen receptor T-cell (CAR-T) therapy has rapidly reshaped the therapeutic landscape for children and adolescents with relapsed or refractory hematologic malignancies. In Brazil, the integration of CAR-T therapy into pediatric oncology practice faces unique logistical, regulatory, and socioeconomic challenges, highlighting the need for ...
Antonella Zanette +6 more
+14 more sources
Advances in CAR-T-cell therapy in T-cell malignancies
Journal of Hematology & OncologySignificant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of
Rubing Zheng, Xiaojian Zhu, Yi Xiao
doaj +3 more sources
Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions
Cells, 2023 T cells expressing chimeric antigen receptors (CARs) are at the forefront of clinical treatment of cancers. Still, the nanoscale organization of CARs at the interface of CAR-Ts with target cells, which is essential for TCR-mediated T cell activation ...
Julia Sajman +7 more
doaj +1 more source
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Frontiers in Immunology, 2022 Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies.
Xiaomin Zhang +6 more
doaj +1 more source
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Frontiers in Immunology, 2023 Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been substantially improved with the emergence of novel therapeutic agents, such as proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies ...
Xiaomin Zhang +4 more
doaj +1 more source
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Biomarker Research, 2021 B-cell non-Hodgkin lymphoma (B-NHL) is a group of heterogeneous disease which remains incurable despite developments of standard chemotherapy regimens and new therapeutic agents in decades.
Zixun Yin, Ya Zhang, Xin Wang
doaj +1 more source